LLY

1,035.94

-2.19%↓

JNJ

205.55

+0.8%↑

ABBV

228.16

+1.59%↑

UNH

336.3

+3.1%↑

AZN

90.85

+0.25%↑

LLY

1,035.94

-2.19%↓

JNJ

205.55

+0.8%↑

ABBV

228.16

+1.59%↑

UNH

336.3

+3.1%↑

AZN

90.85

+0.25%↑

LLY

1,035.94

-2.19%↓

JNJ

205.55

+0.8%↑

ABBV

228.16

+1.59%↑

UNH

336.3

+3.1%↑

AZN

90.85

+0.25%↑

LLY

1,035.94

-2.19%↓

JNJ

205.55

+0.8%↑

ABBV

228.16

+1.59%↑

UNH

336.3

+3.1%↑

AZN

90.85

+0.25%↑

LLY

1,035.94

-2.19%↓

JNJ

205.55

+0.8%↑

ABBV

228.16

+1.59%↑

UNH

336.3

+3.1%↑

AZN

90.85

+0.25%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.35 -0.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.33

Max

1.38

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Aktsiakasum	-0.04
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+191.91% upside

Turustatistika
By TradingEconomics
Turukapital	494M
Eelmine avamishind	2.09
Eelmine sulgemishind	1.35

Uudiste sentiment

By Acuity

50%

162 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. dets 2025, 17:29 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2. dets 2025, 16:21 UTC

Tulu

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2. dets 2025, 16:18 UTC

Tulu

Correction to Scotiabank Quarterly Earnings Buoyed Article

2. dets 2025, 23:53 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

2. dets 2025, 22:48 UTC

Tulu

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2. dets 2025, 22:12 UTC

Market Talk

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2. dets 2025, 22:03 UTC

Market Talk

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Global Equities Roundup: Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. dets 2025, 22:00 UTC

Market Talk

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2. dets 2025, 21:56 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. dets 2025, 21:44 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 21:38 UTC

Market Talk

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2. dets 2025, 21:19 UTC

Tulu

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. dets 2025, 20:06 UTC

Market Talk

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2. dets 2025, 19:55 UTC

Market Talk

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2. dets 2025, 19:53 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

2. dets 2025, 19:53 UTC

Market Talk

Tulu

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2. dets 2025, 19:24 UTC

Market Talk

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2. dets 2025, 19:06 UTC

Market Talk

Precious Metals Step Back After Silver Sets Record -- Market Talk

2. dets 2025, 18:27 UTC

Omandamised, ülevõtmised, äriostud

Kraken to Acquire Backed Finance AG

2. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. dets 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. dets 2025, 15:17 UTC

Market Talk

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2. dets 2025, 14:47 UTC

Market Talk

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2. dets 2025, 14:38 UTC

Market Talk

Silver Steps Back From Record Levels -- Market Talk

2. dets 2025, 14:31 UTC

Market Talk

Tulu

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

191.91% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD 191.91%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

162 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.